ATE104553T1 - Cytostatische und cytotoxische wirkstoffkombination zur anwendung in therapeutischen verfahren. - Google Patents

Cytostatische und cytotoxische wirkstoffkombination zur anwendung in therapeutischen verfahren.

Info

Publication number: ATE104553T1
Authority: AT; Austria
Prior art keywords: cytostatic; therapeutic procedures; application; cytotoxic agents; agents combination
Prior art date: 1990-01-04

Application number

AT9090125093T

Other languages

English (en)

Inventor

Michael Prof Dr Zeppezauer

Hans-Peter Dr Leinenbach

Original Assignee

Symbiotec Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-04

Filing date

1990-12-21

Publication date

1994-05-15

1990-12-21 Application filed by Symbiotec Gmbh filed Critical Symbiotec Gmbh

1994-05-15 Application granted granted Critical

1994-05-15 Publication of ATE104553T1 publication Critical patent/ATE104553T1/de

Links

239000000824 cytostatic agent Substances 0.000 title abstract 3
230000001085 cytostatic effect Effects 0.000 title abstract 3
238000002560 therapeutic procedure Methods 0.000 title abstract 2
239000002254 cytotoxic agent Substances 0.000 title 1
229940127089 cytotoxic agent Drugs 0.000 title 1
231100000599 cytotoxic agent Toxicity 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 4
108010033040 Histones Proteins 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
229960004316 cisplatin Drugs 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960000485 methotrexate Drugs 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
229960004528 vincristine Drugs 0.000 abstract 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT9090125093T 1990-01-04 1990-12-21 Cytostatische und cytotoxische wirkstoffkombination zur anwendung in therapeutischen verfahren. ATE104553T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4000154A DE4000154A1 (de)	1990-01-04	1990-01-04	Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
EP90125093A EP0438756B1 (de)	1990-01-04	1990-12-21	Cytostatische und cytotoxische Wirkstoffkombination zur Anwendung in therapeutischen Verfahren

Publications (1)

Publication Number	Publication Date
ATE104553T1 true ATE104553T1 (de)	1994-05-15

Family

ID=6397630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT9090125093T ATE104553T1 (de)	1990-01-04	1990-12-21	Cytostatische und cytotoxische wirkstoffkombination zur anwendung in therapeutischen verfahren.

Country Status (9)

Country	Link
US (1)	US5578571A (de)
EP (1)	EP0438756B1 (de)
JP (1)	JPH0813756B2 (de)
AT (1)	ATE104553T1 (de)
CA (1)	CA2033249C (de)
CZ (1)	CZ283924B6 (de)
DE (2)	DE4000154A1 (de)
SK (1)	SK279960B6 (de)
UA (1)	UA27704C2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5780432A (en) *	1990-12-28	1998-07-14	Allegheny University Of The Health Sciences	Therapeutic method for treatment of carcinoma or autoimmune diseases
WO1996040170A2 (en) *	1995-06-07	1996-12-19	Procept, Inc.	Metal-containing compounds and their use for inhibiting the immune response
DE19715149A1 (de) *	1997-04-11	1998-10-15	Symbiotec Gmbh	Krebstherapeutikum und Diagnose zur Charakterisierung von Krebszellen mit individueller Eigenschaft
US20030017987A1 (en)	1997-04-11	2003-01-23	Michael Zeppezauer	Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
KR100261114B1 (ko) *	1998-01-24	2000-07-01	박종헌	히스톤을 함유하는 류마티스 관절염 치료제 조성물
US6884423B1 (en) *	1998-08-13	2005-04-26	Symbiotec Gmbh	Antimicrobial histone H1 compositions, kits, and methods of use thereof
CN1296974A (zh) *	1999-11-23	2001-05-30	上海博容基因开发有限公司	一种新的多肽——人组蛋白h2a.21和编码这种多肽的多核苷酸
US20040219140A1 (en) *	2001-02-22	2004-11-04	Reiner Class	Compositions and methods for preventing platelet aggregation
DE102005022319A1 (de)	2005-05-10	2006-11-23	Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh	Verwendung von Histonen zu therapeutischen Zwecken
US8778875B2 (en) *	2005-08-05	2014-07-15	Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie, mbH	Use of an active biological substance in abnormal cellular and viral membrane physiologies
US20080138326A1 (en) *	2006-12-06	2008-06-12	Kaneka Corporation	Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
SG194802A1 (en)	2011-05-16	2013-12-30	Genzyme Corp	Induction of immune tolerance by using methotrexate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4902505A (en) *	1986-07-30	1990-02-20	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
JPS63139134A (ja) *	1986-12-02	1988-06-10	Kyowa Hakko Kogyo Co Ltd	Ｔ細胞活性化剤
DE3737274A1 (de) *	1987-11-03	1989-06-01	Rusch Volker	Verwendung von reinem h2a- und/oder h2b-histon als wirksubstanz zur herstellung von arzneimitteln
EP0316030B1 (de) *	1987-11-11	1991-12-18	Akzo N.V.	Vincristin enthaltendes Produkt

1990
- 1990-01-04 DE DE4000154A patent/DE4000154A1/de not_active Withdrawn
- 1990-12-21 AT AT9090125093T patent/ATE104553T1/de not_active IP Right Cessation
- 1990-12-21 EP EP90125093A patent/EP0438756B1/de not_active Expired - Lifetime
- 1990-12-21 DE DE59005456T patent/DE59005456D1/de not_active Expired - Fee Related
- 1990-12-27 CA CA002033249A patent/CA2033249C/en not_active Expired - Fee Related
- 1990-12-28 SK SK6849-90A patent/SK279960B6/sk unknown
- 1990-12-28 CZ CS906849A patent/CZ283924B6/cs not_active IP Right Cessation
- 1990-12-28 JP JP2417523A patent/JPH0813756B2/ja not_active Expired - Fee Related
1991
- 1991-01-03 UA UA4984039A patent/UA27704C2/uk unknown
1994
- 1994-09-22 US US08/310,378 patent/US5578571A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0438756A1 (de)	1991-07-31
SK684990A3 (en)	1999-06-11
UA27704C2 (uk)	2000-10-16
US5578571A (en)	1996-11-26
SK279960B6 (sk)	1999-06-11
JPH0813756B2 (ja)	1996-02-14
CZ684990A3 (cs)	1998-04-15
DE4000154A1 (de)	1991-07-11
CA2033249A1 (en)	1991-07-05
JPH04305535A (ja)	1992-10-28
CZ283924B6 (cs)	1998-07-15
EP0438756B1 (de)	1994-04-20
CA2033249C (en)	1997-01-21
DE59005456D1 (de)	1994-05-26

Similar Documents

Publication	Publication Date	Title
IL267381A (en)	2019-08-29	A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR9814857A (pt)	2001-12-26	Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
ES2167377T3 (es)	2002-05-16	Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ATE104553T1 (de)	1994-05-15	Cytostatische und cytotoxische wirkstoffkombination zur anwendung in therapeutischen verfahren.
ATE444086T1 (de)	2009-10-15	Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
BR0115531A (pt)	2004-02-03	Tratamento de mucosites
DE69333658D1 (de)	2004-11-18	Verfahren zur behandlung von organen und gewebe
ATE209908T1 (de)	2001-12-15	RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ES2178668T4 (es)	2003-06-16	Naftilamidas como agentes del sistema nervioso central.
ATE199167T1 (de)	2001-02-15	Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
ATE202709T1 (de)	2001-07-15	Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
ATE381533T1 (de)	2008-01-15	Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
NO952137D0 (no)	1995-05-30	Antitrombosemiddel
ATE154934T1 (de)	1997-07-15	Aminocyclohexylamide für antiarrhythmische und anästhetische verwendungen
RU94041028A (ru)	1996-09-20	Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE68901172D1 (de)	1992-05-14	(-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
EA200200656A1 (ru)	2002-12-26	НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
HUT71422A (en)	1995-11-28	Use of bradykinin-antagonists for producing pharmaceutical compositions for treating virus diseases
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DE69001988D1 (de)	1993-07-22	Behandlung des schocks mit cyclodextrin und dessen derivaten.

Legal Events

Date	Code	Title	Description
1996-03-15	REN	Ceased due to non-payment of the annual fee